SEC EDGAR·9d ago
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights — Cash, cash equivalents and short-term investments of $69.7 million with cash runway into Q2 2027 · Series X non-voting convertible preferred stock, $0.001 par value, 10,000 shares designated; 4,422 shares issued and outstanding at September 30, 2026 and December 31, 2025 · Series X1 non-voting convertible preferred stock, $0.001 par value, 515,000 shares designated; 75,800 and 110,086 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively (8-K: Results of Operations)
$2.37 at release-24.1% since1.5x volume
$ELDN discussion
Sign in to ask a question or join the discussion.